The Wegovy Tablet and the Wegovy injection both use the same active medicine, semaglutide, but the trial figures reported for each are not identical and they were not studied head-to-head. In separate trials, the injection at its higher licensed dose reported a larger average weight change than the once-daily tablet — though which suits you depends far more on your health, preferences and a clinician's assessment than on the numbers alone.
The short answer
Both forms of semaglutide work in the same way: they mimic a natural gut hormone (GLP-1) that helps control appetite, so you feel fuller sooner and for longer, and the stomach empties more slowly. The medicine is the same molecule; only the way you take it differs.
What differs in the published evidence is the average weight change reported. It is important to understand these come from separate trials with different participants, doses and durations — so they cannot be read as a direct comparison.
What the trial figures actually say
Here are the only efficacy figures we quote, taken directly from each product's trial. These are cross-trial figures, not a head-to-head comparison.
| Product | Dose studied | Trial & duration | Average weight loss |
|---|---|---|---|
| Wegovy injection (once weekly) | 7.2mg | STEP UP, 72 weeks | 20.7% |
| Wegovy Tablet (once daily) | 25mg | OASIS 4, 64 weeks | 16.6% |
In the STEP UP clinical trial, adults on the 7.2mg dose lost on average 20.7% of their body weight over 72 weeks, alongside lifestyle support. Individual results vary; not everyone reaches this.
In the OASIS 4 trial, adults on oral semaglutide 25mg lost on average 16.6% of their body weight over 64 weeks, alongside lifestyle support. Individual results vary; not everyone reaches this.
Because these were separate trials over different lengths of time, the percentages are not directly comparable. They tell you what each option achieved in its own study — not that one will outperform the other for you personally.
Why the way you take it matters
The biggest practical difference is not the molecule but the delivery. Getting the medicine absorbed reliably is central to how well it works.
The injection
The Wegovy injection is a once-weekly self-injection. It titrates gradually: 0.25mg for weeks 1–4, then 0.5, 1, 1.7, 2.4mg, up to a 7.2mg maximum licensed dose (the standard dose is 2.4mg). Weekly dosing means the medicine level stays steady and you only think about it once a week.
The tablet
The Wegovy Tablet is a once-daily tablet, titrating from a 1.5mg starter through 4 and 9mg to a 25mg maintenance dose. It has a strict usage rule that directly affects how well it works: take it first thing on an empty stomach with a small sip of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medicines.
This matters because oral semaglutide is absorbed poorly when taken with food. Taken incorrectly, it is far less effective — so daily consistency is part of the treatment, not an optional extra. The Wegovy Tablet launched in July 2026 and is in stock.
Which option might suit you?
There is no single "best" choice — the right option depends on your medical history, lifestyle and a prescriber's judgement. As general education, some people weigh it up like this:
- You may lean towards the injection if you prefer dosing once a week, find a daily empty-stomach routine hard to keep, or want the option with the higher reported trial figure.
- You may lean towards the tablet if you would rather avoid needles and can reliably take a tablet each morning and wait 30 minutes before your day starts.
A third medicine, Mounjaro (tirzepatide), works on two gut-hormone receptors rather than one, and Foundayo (orforglipron) is a once-daily pill expected in the UK once MHRA-licensed. You can see everything side by side on our treatments overview and weight-loss injections pages.
Who is eligible?
Eligibility is the same across the semaglutide options. You may be suitable if you are aged 18 or over and have a BMI of 30 or more, or a BMI of 27–30 with a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea.
These medicines are not suitable if you are pregnant, planning pregnancy or breastfeeding, have type 1 diabetes, a personal or family history of medullary thyroid cancer or MEN2, a history of pancreatitis, severe gastrointestinal disease, an active eating disorder, severe liver or kidney impairment, or a known allergy to the active ingredient.
Both the tablet and the injection are Prescription-Only Medicines. They are available only after a clinical consultation with a GPhC-registered prescriber, who decides if a treatment is clinically appropriate. A prescription or a specific outcome can never be guaranteed. You can start with our free online eligibility check.
Side effects to be aware of
Because it is the same active medicine, the side-effect profile is similar for both forms. The most common effects (affecting more than 1 in 10 people) include nausea, diarrhoea, constipation, vomiting, decreased appetite and fatigue. These are often strongest early on and tend to ease as your body adjusts, which is one reason the dose is increased slowly.
Rare but serious risks include severe allergic reaction, acute pancreatitis, severe hypoglycaemia and severe gastrointestinal disease. Seek medical help if you experience severe or persistent symptoms.
If you experience a side effect, you can report it through the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/. Reporting helps monitor the safety of medicines.
The bottom line
Neither medicine cures obesity, and no medicine replaces the lifestyle support that both trials included. The injection reported a higher average figure in its own trial, but because the studies were separate, this does not prove it will work better for any one person. The most effective option is the one you can take correctly and consistently, chosen with a prescriber who knows your history.
If you would like to explore your options, our free consultation is the place to begin. You can also read more on the blog or contact us with questions.
This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.
